Download PDF
Frauenheilkunde up2date 2021; 15(02): 119-137
DOI: 10.1055/a-1068-7370
Geburtshilfe und Perinatalmedizin

Tokolyse

Werner Rath
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Die medikamentöse Wehenhemmung (Tokolyse) gehört nach der Geburtseinleitung zu den häufigsten Maßnahmen in der Geburtshilfe. Unsicherheiten bestehen vor allem hinsichtlich der Indikation zur Tokolyse. Bisher gibt es nicht das für Mutter und Kind „ideale“ Tokolytikum. Die Erhaltungstokolyse ist eine Einzelfallentscheidung im Spannungsfeld zwischen Evidenz und klinischer Praxis.
Kernaussagen

  • Die Tokolyse gehört zu den häufigsten Maßnahmen in der Geburtshilfe.

  • Die Indikationen sind regelmäßige, vorzeitige Wehen ≥ 4/20 min in Verbindung mit einer Verkürzung/Eröffnung der Zervix zwischen 22 + 0 und 33 + 6 SSW.

  • Ziel ist die Schwangerschaftsverlängerung um 48 Stunden zum Abschluss der fetalen Lungenreifeinduktion und zum In-utero-Transfer der Schwangeren in ein Perinatalzentrum.

  • Geeignete Tokolytika sind vor allem Indometacin, Nifedipin und Atosiban.

  • Die Erhaltungstokolyse (> 48 h) ist eine Einzelfallentscheidung, aber keine evidenzbasierte Maßnahme zur Senkung der Frühgeburtenrate.

  • Vaginales/orales Progesteron wird derzeit weder in Kombination mit einem Tokolytikum noch zur Erhaltungstherapie empfohlen.

Schlüsselwörter

Pathophysiologie - Indikation - Kontraindikation - Evidenz - Tokolytika


Publication History

Article published online:
07 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Zeitling J, Szamolusha K, Drewnick N. et al. Preterm birth time trends in Europe, a study of 19 countries. Br J Obstet Gynaecol 2013; 120: 1356-1365
    CrossrefPubMedGoogle Scholar
  • 2 IQTIG: Institut für Qualitätssicherung und Transparenz im Gesundheitswesen 2018. Basisauswertung zum Erfassungsjahr 2017: Geburtshilfe. Im Internet (Stand: 03.08.2020): http://www.iqtig.org
    Google Scholar
  • 3 Vogel IP, Chawanpaiboon S, Moller AB. et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52: 3-12
    CrossrefPubMedGoogle Scholar
  • 4 AWMF-Leitlinie (S2k): Prävention und Therapie der Frühgeburt 2019. Im Internet (Stand: 05.08.2020): https://www.awmf.org/uploads/tx-szleitlinien/015-025l-s2k
    Google Scholar
  • 5 Romero R, Dey SK, Fischer SJ. Preterm labor: one syndrome, many causes. Science 2014; 345: 760-765
    CrossrefPubMedGoogle Scholar
  • 6 Syhes L, Bennett PP. Efficacy of progesterone for prevention of preterm birth. Best Pract Res Clin Obstet Gynecol 2018; DOI: 10.1016/j.bpobgyn.2018.08.006.
    CrossrefPubMedGoogle Scholar
  • 7 Kuon JR, Abele H, Berger R. et al. Progesterone for prevention of preterm birth – evidence-based indications. Z Gebh Neonatal 2015; 219: 125-135
    Google Scholar
  • 8 Berger R, Kienast C. Molekulare Grundlage der Frühgeburt. In: Liedtke C, Rody A. Hrsg. Molekulare Gynäkologie und Geburtshilfe. Berlin, Heidelberg: Springer; 2016: 61-68
    Google Scholar
  • 9 Eloritz MA, Wang Z, Chien EK. et al. A new model for inflammation-induced preterm birth. Am J Pathol 2003; 163: 2103-2111
    CrossrefPubMedGoogle Scholar
  • 10 Han CS, Schatz F, Lockward CJ. Abruption-associated prematurity. Clin Perinatol 2011; 38: 407-421
    CrossrefPubMedGoogle Scholar
  • 11 Kim YM, Bujold E, Chaiworapongsa T. et al. Failure of physiology transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003; 189: 1663-1669
    Google Scholar
  • 12 ACOG Practice Bulletin No. 171. Management of preterm labour. Obstet Gynecol 2016; 128: e155-e164
    CrossrefPubMedGoogle Scholar
  • 13 Hackney DN, Olson-Chen C, Thomberg LL. What do we know above the natural outcomes of preterm labour? A systematic review and meta-analysis of women without tocolysis in preterm labour. Paediatr Perinat Epidemiol 2013; 27: 452-460
    CrossrefPubMedGoogle Scholar
  • 14 Nijman TAJ, van Vliet EOG, Koullali B. et al. Antepartum and intrapartum interventions to prevent preterm birth and its sequelae. Semin Fetal Neonatal Med 2016; 21: 121-128
    CrossrefPubMedGoogle Scholar
  • 15 Kagan KO, Sonek J. How to measure the cervix length?. Ultrasound Obstet Gynecol 2015; DOI: 10.1002/uog.14742.
    CrossrefPubMedGoogle Scholar
  • 16 Onderoglu LS. Digital examination and transperineal ultrasonographic measurement of cervical length to assess risk of preterm delivery. Int J Gynaecol Obstet 1997; 59: 223-228
    CrossrefPubMedGoogle Scholar
  • 17 De Franco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labour: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol 2013; 208: 233.e1-233.e6
    CrossrefPubMedGoogle Scholar
  • 18 Society for Maternal-Fetal Medicine (SMFM). Mc Intosh J, Feltovich H. et al. The role of routine cervical length screening in selected high- and low-risk women with preterm birth prevention. Am J Obstet Gynecol 2016; 215: B2-B7
    CrossrefPubMedGoogle Scholar
  • 19 De Renzo GC, Roura LC, Facchinetti F. et al. Preterm labor and birth management: Recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med 2017; 30: 2011-2030
    CrossrefPubMedGoogle Scholar
  • 20 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451
    CrossrefPubMedGoogle Scholar
  • 21 van Baaren GJ, Vis JY, Wilms FF. et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123: 1185-1192
    CrossrefPubMedGoogle Scholar
  • 22 Berghella V, Saccone G. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2016; 215: 431-438
    CrossrefPubMedGoogle Scholar
  • 23 van Baaren GJ, Vis JY, Grobman WA. et al. Cost-effectiveness analysis of cervical length measurement and fibronectin testing in women with threatened labor. Am J Obstet Gynecol 2013; 209: 436.e1-436.e8
    CrossrefPubMedGoogle Scholar
  • 24 Lange TS, Roos C, Bloemenkamp KW. et al. Impact of a randomized trial on maintenance tocolysis on length of hospital admission of women with threatened preterm labor in the Netherlands. Eur J Obstet Gynecol Reprod Biol 2015; 186: 8-11
    CrossrefPubMedGoogle Scholar
  • 25 Rath W, Kehl S. Akuttokolyse – eine kritische Analyse evidenzbasierter Daten. Geburtshilfe Frauenheilkd 2018; 78: 1245-1255
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 NICE Guideline. Preterm labour and birth 2015. Im Internet (Stand: 05.08.2020): http://www.nice.org.uk/guidance/ng25
    Google Scholar
  • 27 Navathe R, Berghella V. Tocolysis for acute preterm labour: Where have we been, where are we now, and where are we going?. Am J Perinatol 2016; 33: 229-235
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Haas DM, Imperiale TF, Kirkpatrick PR. et al. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585-594
    CrossrefPubMedGoogle Scholar
  • 29 Haas DM, Caldwell DM, Kirkpatrick PR. et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. Br Med J 2012; 345: e6226
    CrossrefPubMedGoogle Scholar
  • 30 Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (02) CD004352
    PubMedGoogle Scholar
  • 31 de Heus R, Mol BW, Erwich JJ. et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. Br Med J 2009; 338: b744
    CrossrefPubMedGoogle Scholar
  • 32 Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004; (04) CD004352
    PubMedGoogle Scholar
  • 33 Herzog S, Cunze T, Martin M. et al. Pulsatile vs. continuous parenteral tocolysis: comparison of side effects. Eur J Obstet Gynecol Reprod Biol 1999; 85: 199-206
    CrossrefPubMedGoogle Scholar
  • 34 Conde-Agudelo A, Romero R. Transdermal nitroglycerin for the treatment of preterm labour: a systematic review and meta-analysis. Am J Obstet Gynecol 2013; 209: 551.e1-551.e18
    CrossrefPubMedGoogle Scholar
  • 35 Duckitt K, Thornton S, OʼDonnovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database Syst Rev 2014; (05) CD002860
    PubMedGoogle Scholar
  • 36 Reinebrant HE, Pileggi-Castro C, Romero CLT. et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2015; (06) CD001992
    PubMedGoogle Scholar
  • 37 Sandrock JC, Grobman WA, Garbour SE. The effect of short-term indomethacin therapy on amniotic fluid volume. Am J Obstet Gynecol 2005; 192: 1443-1445
    CrossrefPubMedGoogle Scholar
  • 38 Hammers AL, Sanchez-Romero L, Kaunitz AM. Antenatal exposure to indomethacin increased the risk of severe intraventricular haemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. Am J Obstet Gynecol 2015; 212: 505.e1-505.e13
    CrossrefPubMedGoogle Scholar
  • 39 Turan OM, Driscall C, Cetinkaya-Demir B. et al. Prolonged early antenatal indometacin exposure is safe for fetus and neonate. J Matern-Fetal Neonatal Med 2019; DOI: 10.1080/14767058.2019.1599351.
    CrossrefPubMedGoogle Scholar
  • 40 Vogel JP, Oladapo OT, Manu A. et al. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health 2015; 3: e589
    CrossrefPubMedGoogle Scholar
  • 41 Crowther CA, Brown J, Mc Kinlay CJD. et al. Magnesium sulphate for preventing preterm birth in threatened labour. Cochrane Database Syst Rev 2014; (08) CD001060
    PubMedGoogle Scholar
  • 42 Lewis DF. Magnesium sulfate: the first-line tocolytic. Obstet Gynecol Clin North Am 2005; 113: 485-500
    CrossrefPubMedGoogle Scholar
  • 43 Lyell DJ, Pullen K, Campbell L. et al. Magnesium sulphate compared with Nifedipine for acute tocolysis of preterm labor. Obstet Gynecol 2007; 110: 61-67
    CrossrefPubMedGoogle Scholar
  • 44 Xiao C, Gangal M, Abenhaim HA. Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. J Perinatal Med 2014; 42: 585-588
    CrossrefPubMedGoogle Scholar
  • 45 Flenady V, Wojcieszek AM, Papatsonis DNM. et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev 2014; (06) CD002255
    PubMedGoogle Scholar
  • 46 van Vliet EOG, Nijman TAJ, Schuit E. et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet 2016; 387: 2117-2124
    CrossrefPubMedGoogle Scholar
  • 47 Oei SG. Calcium channel blockers for tocolysis: A review of their role and safety following reports of serious adverse events. Eur J Obstet Gynecol Reprod Biol 2006; 126: 137-145
    CrossrefPubMedGoogle Scholar
  • 48 Khan K, Zamora J, Lamont RF. et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. J Matern Fetal Neonatal Med 2010; 23: 1020-1038
    CrossrefPubMedGoogle Scholar
  • 49 Sentilhes L, Senat M-V, Ancel PY. et al. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2017; 210: 217-224
    CrossrefPubMedGoogle Scholar
  • 50 Flenady V, Reinebrant HE, Lieley HG. et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (06) CD004452
    PubMedGoogle Scholar
  • 51 Nonnenmacher A, Hopp H, Dudenhausen J. Wirksamkeit und Sicherheit von Atosiban vs. pulsatiler Applikation von Fenoterol bei der Behandlung vorzeitiger Wehen. Z Geburtsh Neonatol 2009; 213: 201-206
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Royal College of Obstetrics and Gynaecologists (RCOG). Green-top guideline 2011, No. 1b. Tocolysis for women in preterm labour. Im Internet (Stand: 05.08.2020): https://www.wis.dom.wales.nhs.uk/openedoc/296835
    Google Scholar
  • 53 Vogel IP, Nardin JM, Dowswell T. et al. Combination of tocolytic agents for inhibitory labour. Cochrane Database Syst Rev 2014; (07) CD006169
    PubMedGoogle Scholar
  • 54 Rath W, Kuon R-J. Progesteron- effektiv zur Wehenhemmung und zur Erhaltungstokolyse nach Wehenstopp?. Geburtshilfe Frauenheilkd 2019; 79: 834-843
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 MacKeen AD, Seibel-Seaman J, Muhammad J. et al. Tocolytical for preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; (02) CD007062
    PubMedGoogle Scholar
  • 56 Miyazaki C, Moreno Garcia R, Ota E. et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reproductive Health 2016; 13: 7
    PubMedGoogle Scholar
  • 57 Yamasmit W, Chaithongwongwatthana S, Tolosa JE. et al. Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy. Cochrane Database Syst Rev 2015; (12) CD004733
    PubMedGoogle Scholar
  • 58 Stelzl P, Kehl S, Rath W. Maintenance tocolysis: a reappraisal of clinical evidence. Arch Gynecol Obstet 2019; 300: 1189-1199 doi:10.1007/s00404-019-05313-7
    CrossrefPubMedGoogle Scholar
  • 59 Gaunekar NN, Rama P, Crowther CA. Maintenance therapy with calcium channel blocker for preventing preterm birth after threatened labour. Cochrane Database Syst Rev 2013; (10) CD004071
    PubMedGoogle Scholar
  • 60 van Vliet E, Dijkema G, Schuit E. et al. Nifedipine maintenance tocolysis and perinatal outcome, an individual participant data meta-analysis. Br J Obstet Gynaecol 2016; 123: 1753-1760
    CrossrefPubMedGoogle Scholar
  • 61 Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (05) CD000940
    PubMedGoogle Scholar
  • 62 Suhag A, Saccone G, Berghella V. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomised trials. Obstet Gynecol 2015; 213: 479-487
    Google Scholar
  • 63 Eke AC, Chalaen T, Shuker G. et al. A systematic review and meta-analysis of progesterone use for maintenance tocolysis after preterm labour in women with intact membranes. Int J Gynecol Obstet 2016; 132: 11-16
    CrossrefPubMedGoogle Scholar
  • 64 Palacio M, Rontoni S, Sanchez-Romero I. et al. Progesterones and maintenance treatment in arrested preterm labour: a systematic review and meta-analysis. Obstet Gynecol 2016; 128: 989-1006
    CrossrefPubMedGoogle Scholar
  • 65 Wood S, Radi Y, Tang S. et al. Progesterone in women with arrested premature labour – a report of randomised clinical trials and updated meta-analysis. BMC Pregnancy Childbirth 2017; 17: 258
    CrossrefPubMedGoogle Scholar
  • 66 Sosa CG, Althabe F, Beliton JM. et al. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2015; (03) CD003581
    PubMedGoogle Scholar
  • 67 da Silva Lopes K, Takemoto Y, Ota E. et al. Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes. Cochrane Database Syst Rev 2017; (03) CD012031
    PubMedGoogle Scholar